You are here

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

Last updated on November 13, 2019

Study Location
San Diego, California, 92108 United States
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-63 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
All Genders
Multiple Sites
Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
All Genders
Multiple Sites
Advanced Breast Cancer, Metastatic Breast Cancer
All Genders
Multiple Sites
Descriptive Information
Brief TitleEffect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
Official TitleEvaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW
Brief Summary

It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense. However, while breast density may be a risk factor, the etiology of the relationship between breast cancer and breast density is not understood. Furthermore, it is well recognized that breast cancer can still develop in women whose breasts are not dense.

At menopause, the amount of breast glandular tissue and stroma naturally decreases due to a lack of hormonal stimulation. This is characterized as a decrease in the mammographic density. Although certain medications, including hormone therapy (HT) and dopamine antagonists can increase breast density, these effects are reversible upon discontinuation of the specific agent. Other medications such as the selective estrogen receptor modulators (SERM), raloxifene (RAL) and tamoxifen, have been shown to not affect breast density and allow the normal age-related changes to occur. The effects of bazedoxifene (BZA), a new SERM, on breast density are not known. The purpose of this study is to examine the effect of BZA on breast density changes over 24 months in postmenopausal women. The results may be useful for clinicians to understand the effect of BZA on breast density and its mammographic effects.

This is an observational, multicenter, double-blind, randomized, placebo- and active comparator-controlled study. It is also an ancillary that will use women who are already participants in a phase 3 trial for fracture reduction (protocol 3068A1-301-WW; primary study). In the primary study, subjects received BZA 20 mg, BZA 40 mg, RAL 60 mg, or placebo. This ancillary study will request a subset of participants to use their mammograms taken in this study. Their mammogram will be digitized by a central imaging center. A single radiologist will perform the quantifications of breast density from the digitized mammograms.

Detailed DescriptionNot Provided
Study TypeObservational
Study DesignTime Perspective: Retrospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNot Provided
Study PopulationNot Provided
ConditionBreast Cancer
InterventionNot Provided
Study Groups/CohortsNot Provided
Publications *Not Provided

*   Includes publications given by the data provider as well as publications
identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment StatusCompleted
 (submitted: January 2, 2007)
Original EnrollmentSame as current
Actual Study Completion DateApril 2010
Primary Completion DateNot Provided
Eligibility Criteria
  1. Each subject must have participated or is currently participating in study 3068A1 301, and must satisfy all of the following criteria
  2. Has completed 24 months of treatment.
  3. Had a mammogram at the baseline visit and at the month 24 visit, and both are original films that are technically acceptable for reading.
  4. Was less than or equal to 62 years of age at the time of study randomization in the primary study.
  5. Was at least 80% compliant with test article administration.
  6. Did not take any medications 6 months prior to screening in the primary study or during the first 24 months of the study that could cause a change in breast density.
  7. Was enrolled at a site that has at least 4 subjects meeting all of the above inclusion criteria.
  8. Was enrolled at a clinical site that is still participating in the primary study.
Sexes Eligible for Study:Female
Ages18 Years to 63 Years   (Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesArgentina,   Brazil,   Bulgaria,   Canada,   Chile,   Croatia,   Denmark,   Estonia,   Mexico,   Netherlands,   Poland,   Romania,   South Africa,   United States
Removed Location Countries  
Administrative Information
NCT NumberNCT00418236
Other Study ID Numbers3068A1-400
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyNot Provided
Study SponsorWyeth is now a wholly owned subsidiary of Pfizer
CollaboratorsNot Provided
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor Bulgaria, [email protected]
Principal Investigator:Trial ManagerFor Croatia, [email protected]
Principal Investigator:Trial ManagerFor Denmark, [email protected]
Principal Investigator:Trial ManagerFor Estonia, [email protected]
Principal Investigator:Trial ManagerFor Netherlands, [email protected]
Principal Investigator:Trial ManagerFor Poland, [email protected]
Principal Investigator:Trial ManagerFor Romania, [email protected]
Principal Investigator:Trial ManagerFor South Africa, [email protected]
Principal Investigator:Trial ManagerFor Canada, [email protected]
Principal Investigator:Trial ManagerFor Mexico, [email protected]
Principal Investigator:Trial ManagerFor Argentina, [email protected]
Principal Investigator:Trial ManagerFor Chile, [email protected]
Principal Investigator:Trial ManagerFor Brazil, [email protected]
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateDecember 2007


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now